

FTC Expands Orange Book Patent Listing Challenges

A photograph of a modern building with a curved glass facade, showing multiple floors and windows, set against a light blue sky.

1 MIN READ

April 30, 2024, 11:53 AM

By: Matthew S. Murphy, Ross E. Blau

As discussed in [November](#) and [December](#), the FTC has placed improper Orange Book patent listings squarely in its crosshairs. Initially, based on its [September 2023 policy statement](#), FTC announced that it would “scrutinize improper Orange Book listings” and “use its full legal authority” to “tak[e] actions against companies and individuals that improperly list patents in the Orange Book that do not meet the statutory listing criteria.” Towards the end of last year, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in the FDA’s Orange Book for a variety of products is improper, in addition to notifying the FDA of what it believed were [improper listings](#).

Since then, the FTC has been somewhat quiet, choosing not to sue any of these pharmaceutical companies on its own, but supporting the policy statement by filing two amicus briefs, [one](#) regarding the Lantus drug product and [the other](#) regarding asthma inhalers.


[Today](#), the FTC announced another set of 10 letters regarding 300 Orange Book patent listings across 20 different brand name products. It is unclear if the FTC will take action against these pharmaceutical companies or continue to file amicus briefs in cases where these patents are at issue. Time will tell whether the FTC’s actions result in any patent delistings or changes in the Orange Book. But it’s clear that the FTC intends to remain active in this area.



Related People



Matthew S. Murphy



Ross E. Blau

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

TAGS

regulatory

News & Insights

- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- Evidence for Trial Lawyers: Motions, Introducing Evidence, and Objections
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- NYC Bar Trade Secrets Symposium 2024: Navigating the Law of Trade Secrets and Restrictive Covenants
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Stakeholders 24th Annual CYOC Career Development Conference
SPONSORSHIP
- IAM Connect Patent Policy and Litigation Conference 2024
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- CompLaw 33rd Annual Advanced EU Brussels Conference
SPEAKING ENGAGEMENT ANTITRUST
- Jason Murata Named a Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner
AWARDS & RECOGNITIONS INTELLECTUAL PROPERTY
- AIC General Counsel Day 2024
SPEAKING ENGAGEMENT ANTITRUST
- ALM General Counsel Conference East 2024
SPEAKING ENGAGEMENT ANTITRUST
- Global M&A Antitrust Outlook: Trends Shaping Enforcement Strategies
SPEAKING ENGAGEMENT ANTITRUST

